Characteristics of patients receiving extended treatment after incident venous thromboembolism
- 9 July 2021
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 129 (4) , 332-342
Abstract
Given high recurrence risk after venous thromboembolism (VTE), guidelines recommend extended dose rivaroxaban (10 mg OD) or apixaban (2.5 mg BID) to be considered after 6 months of initial treatment. This study aimed to provide insight into clinical practice regarding use of extended preventive treatment, and to describe duration of the initial treatment. Linkage of nationwide health registers identified all in- and outpatients with VTE from April 2017 through 2018. Hazard ratios (HR) with 95% confidence intervals (CIs) were calculated adjusting for other VTE-related factors. The study included 6,030 patients with VTE. Among rivaroxaban users, 2.2% (n=113) received the extended 10 mg dose after mean 9.4 (SD 3.1) months of standard treatment. For apixaban, 4.7% (n=40) received extended 2.5 mg dose after mean 8.0 months (SD 3.9). After adjustments, incident pulmonary embolism (HR 1.81 95% CI 1.12;2.91), and trauma/fracture (HR 1.42 95% CI 0.46;4.43) were associated with switching to extended dose, whereas patients with unprovoked VTE were less likely to receive the extended dose (HR 0.68 95% CI 0.30;1.55). Less than 3% of patients with incident VTE received extended treatment after initial standard treatment. Even though international guidelines suggest that the risk–benefit balance is in favour of extended VTE treatment, this was yet to be translated into clinical practice as of 2018. Studies using contemporary data are warranted to investigate routine clinical practice of extended treatment for VTE recurrence.Keywords
Funding Information
- Bayer
This publication has 25 references indexed in Scilit:
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary EmbolismJAMA, 2015
- 30-Year Mortality After Venous ThromboembolismCirculation, 2014
- Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case–control studyJournal of Thrombosis and Haemostasis, 2014
- The Danish Civil Registration System as a tool in epidemiologyEuropean Journal of Epidemiology, 2014
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with cautionJournal of Clinical Epidemiology, 2010
- Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapyCanadian Medical Association Journal, 2008